Compare Hewlett Packard Enterprise Co (HPE) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hewlett Packard Enterprise Co vs Merck & Co., Inc. — how do they compare? Hewlett Packard Enterprise Co trades at $73.46 (market cap $94.25B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 3.7× Hewlett Packard Enterprise Co's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Hewlett Packard Enterprise Co for 33 Days and Merck & Co., Inc. for 98 Days on average.
| HPE | MRK | |
|---|---|---|
Market Cap | $94.25B | $351.28B |
Volume | 16,060,854 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $73.46 | $156.43 |
52-Week Low | $20.01 | $82.49 |
Typical Hold Time | 33 Days | 98 Days |
Enterprise Value | $108.28B | $398.04B |
Dividend Yield | 0.8% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hewlett Packard Enterprise (HPE) trades at $70.99, down 1.56% today but near its 52-week high following strong AI-driven momentum. The stock has gained over 160% year-over-year, supported by recent earnings beats and a $1.2 billion AI infrastructure order from Vultr. Technical indicators show bullish moving averages but overbought RSI levels, while fundamentals reveal robust revenue growth projections to $41.9 billion in 2026 despite margin compression in 2025.
HPE presents a compelling growth story fueled by AI infrastructure demand, with analyst consensus leaning bullish (47.5% Buy ratings) and a $70.35 price target. Key risks include elevated valuation multiples (P/E 36.6) and execution challenges in integrating Juniper Networks, but raised guidance and institutional upgrades signal confidence in near-term upside.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
